AnjayRastogiMDPhD

Nephrology • Los Angeles, CA

Professor, Medicine, UCLA School of Medicine

Join to view full profile

Dr. Rastogi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rastogi's full profile

Already have an account?

Office
200 Medical Plaza
#365B
Los Angeles, CA 90095
Phone+1 310-954-2692

Summary

Anjay Rastogi, M.D., Ph.D, is Professor and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, Los Angeles, California. Dr. Rastogi is board certified in Nephrology and has a doctoral degree (Ph.D) in Pharmacology. Dr. Rastogi did his Internal Medicine residency and Nephrology fellowship at UCLA; he completed his graduate training under the mentorship of Nobel Laureate Professor, Louis Ignarro also at UCLA. Besides the Clinical Chief, he also serves as the Director of Nephrology Clinical Research Program, Medical Director of the ESRD | Dialysis Program, Living Kidney Donor Program, Fabry Program and PKD Program at UCLA. His research interests include cardiovascular disease, PKD, Fabry disease, anemia, diabetes and hypertension, especially in the CKD population; he has several ongoing clinical trials and studies including the NIH sponsored SPRINT study. He founded the CORE Kidney Program and the Bruin Beans Health Club at UCLA. He was awarded the UCLA Exceptional MD of the Year Award in 2014 for his demonstration of the UCLA values of Compassion, Respect, Excellence, Discovery, Integrity, and Teamwork.

Kidney Health Fair 2018 | UCLAMDCHAT

Join UCLA nephrologist Anjay Rastogi, MD, for a conversation about the annual UCLA Kidney Health Fair. Dr. Rastogi introduces a kidney patient and a kidney dono

Steps and Challenges in Kidney Transplantation | Anjay Rastogi, MD, PhD

UCLA nephrologist Anjay Rastogi, MD, and transplant coordinator Bethany Durban, MDS, talk about kidney transplantation, including wait list times and processes

UCLA UKEEP Event: Living Kidney Donor - Patient Stories | UCLA Nephrology

The UCLA CORE Kidney Program presents its UKEEP Event on Living Kidney Donors. Dr. Anjay Rastogi, Medical Director of UCLA Living Kidney Donor Program, opens up

Kidney Transplantation: Living Kidney Donation - Anjay Rastogi, MD, PhD | UCLAMD

UCLA nephrologist Anjay Rastogi, MD, and Living Donor Transplant Coordinator Suzanne McGuire, RN, BSN, CCTC, talk about kidney transplantation, the importance o

Blood Pressure and U | Anjay Rastogi, MD - UCLA Health

UCLA nephrologist Anjay Rastogi, MD, discusses the importance of controlling and managing high blood pressure through lifestyle and medication management. Learn

Polycystic Kidney Disease (PKD) - Anjay Rastogi, MD | UCLAMDCHAT Webinar

UCLA nephrologist Anjay Rastogi, MD, gives an overview of Polycystic Kidney Disease (PKD), including causes, symptoms, diagnosis and treatment. Learn more at ht

CORE Kidney, Los Angeles, CA

"Our mission is to improve healthcare delivery to patients with kidney disease by implementing our CORE values of Clinical Excellence, Outreach, Research, and E

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Nephrology, 2003 - 2005
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2000 - 2003
University of California, Los AngelesPhD, Pharmacology, 1994 - 2000
University of California, Los AngelesPh.D., Pharmacology, 1994 - 2000
Sawai Man Singh Medical CollegeClass of 1993

Certifications & Licensure

CA State Medical License 2003 - 2025
American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

Physician of the Year University of California, Los Angeles, 2014

Clinical Trials

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Start of enrollment: 2007 Jan 01
Completed
Phase 3
Tolvaptan Extension Study in Participants With ADPKD Start of enrollment: 2010 May 26
Completed
Phase 3
Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia Start of enrollment: 2010 Sep 01
Completed
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease Start of enrollment: 2012 Oct 11
Completed
Phase 1, Phase 2
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease Start of enrollment: 2013 Mar 18
Terminated
Phase 2
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis Start of enrollment: 2013 Sep 03
Completed
Phase 3
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease Start of enrollment: 2014 May 01
Completed
Phase 3
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis Start of enrollment: 2014 Jun 26
Completed
Phase 3
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Start of enrollment: 2014 Oct 17
Completed
Phase 3
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis Start of enrollment: 2015 Jan 15
Completed
Phase 3
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis Start of enrollment: 2014 Nov 21
Completed
Phase 3
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease Start of enrollment: 2015 Sep 17
Completed
Phase 3
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Start of enrollment: 2015 Sep 17
Completed
Phase 3
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 Start of enrollment: 2015 Dec 25
Terminated
Phase 2
Efficacy of Tolvaptan on ADPKD Patients Start of enrollment: 2016 Oct 01
Active, not recruiting
Not Applicable
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function Start of enrollment: 2016 Jun 01
Completed
Phase 3
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) Start of enrollment: 2016 Sep 27
Completed
Phase 3
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Start of enrollment: 2016 Sep 28
Completed
Phase 3
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) Start of enrollment: 2017 May 11
Completed
Phase 3
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP) Start of enrollment: 2017 Jul 27
Completed
Phase 2
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD Start of enrollment: 2017 Oct 12
Completed
Phase 2
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Start of enrollment: 2017 Dec 26
Completed
Phase 2
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) Start of enrollment: 2018 Sep 05
Completed
Phase 3
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ) Start of enrollment: 2018 Mar 05
Completed
Phase 3
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients Start of enrollment: 2018 Oct 04
Terminated
Phase 2, Phase 3
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. Start of enrollment: 2021 May 06
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode.
Charles V Pollack Jr, David Arroyo, Eiichiro Kanda, Ignacio José Sánchez Lázaro, Eva Lesén
ESC Heart Failure. 2024-12-10
Utilization of Potassium Binders for the Management of Hyperkalemia in Chronic Kidney Disease: A Position Statement by US Nephrologists.
Anjay Rastogi, Glenn M Chertow, Ashté Collins, Ellie Kelepouris, Wayne Kotzker
Advances in Kidney Disease and Health. 2024-11-01
Summary of Research: Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA an...
Navdeep Tangri, Anjay Rastogi, Tadashi Sofue
Advances in Therapy. 2024-11-01

Journal Articles

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Ronald D Perrone, Anjay Rastogi, Terry Watnick, Arlene B Chapman, Michal Mrug, Vicente E Torres, Fouad T Chebib, Neera K Dahl, Peter C Harris, Journal of the American Society of Nephrology
Published Ahead of Print
Anjay Rastogi, Glenn M Chertow, Journal of the American Society of Nephrology
Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal Insufficiency
R. M. Hanna, U. Selamet, P. Bui, S.-F. Sun, O. Shenouda, N. Nobakht, M. Barsoum, F. Arman, and A. Rastogi, Case Reports Nephrol. Dial., 1/1/2018
Case Report: Patient with Hepatitis C, p-ANCA, and Cryoglobulin Antibodies Presenting with Necrotizing Crescentic p-ANCA Glomerulonephritis
R. M. Hanna, N. So, M. Kaldas, J. Hou, F. Arman, M. Sangalang, B. Yanny, U. Selamet, S. Saab, N. Nobakht, and A. Rastogi, Case Reports Nephrol. Dial., 1/1/2018
Staffing Ratios in Hemodialysis Facilities
A. Rastogi and G. M. Chertow, Clin. J. Am. Soc. Nephrol., 1/1/2018
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease�mineral bone disorder parameters in dialysis patients
M. Ketteler, S. M. Sprague, A. C. Covic, A. Rastogi, B. Spinowitz, V. Rakov, S. Walpen, and J. Floege, Nephrol. Dial. Transplant., 1/1/2018
Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients
S. M. Sprague, M. Ketteler, A. C. Covic, J. Floege, V. Rakov, S. Walpen, and A. Rastogi, Hemodial. Int., 1/1/2018
A Case of Kidney Involvement in Primary Sj�gren�s Syndrome
Arman F, Shakeri H, Nobakht N, Rastogi A, Kamgar M, The American Journal of Case Reports, 1/1/2017
Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease: A Secondary Analysis of a Randomized Trial
Srinivasan Beddhu, Michael V. Rocco, Robert Toto, Timothy E. Craven, Tom Greene, Udayan Bhatt, Alfred K. Cheung, Debbie Cohen, Barry I. Freedman, Amret T. Hawfield, An..., Ann Intern Med, 1/1/2017
One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis
Jurgen Floege, Adrian C Covic, Markus Ketteler, Johannes Mann, Anjay Rastogi, Bruce Spinowitz, Viatcheslav Rakov, Laura J Lisk, Stuart M Sprague, Nephrology Dialysis Transplantation, 1/1/2017
Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial
Bharathi Upadhya, Michael Rocco, Cora E. Lewis, Suzanne Oparil, Laura C. Lovato, William C. Cushman, Jeffrey T. Bates, Natalie A. Bello, Gerard Aurigemma, Lawrence J. ..., Circulation: Heart Failure, 1/1/2017
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
Covic, A. C., Floege, J., Ketteler, M., Sprague, S. M., Lisk, L., Rakov, V., & Rastogi, A., Nephrology, Dialysis, Transplantation, 1/1/2016
Patterns and correlates of baseline thiazide �type diuretic prescription in the systolic blood pressure intervention trial (SPRINT)
Chang TI, Evans G, Cheung AK, et al, Hypertension, 1/1/2016
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients
S. M. Sprague, A. C. Covic, J. Floege, M. Ketteler, J. Botha, E. M. Chong, and A. Rastog, Am. J. Nephrol., 1/1/2016
Four-Week Studies of Oral Hypoxia-Inducible Factor�Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia
Holdstock, L., Meadowcroft, A. M., Maier, R., Johnson, B. M., Jones, D., Rastogi, A., � Cobitz, A. R., Journal of the American Society of Nephrology, 1/1/2016
Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM on Behalf of the Sucroferric Oxyhydroxide Study Group, Nephrology Dialysis Transplantation, 1/1/2015
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors
Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators, The New England Journal of Medicine, 1/1/2015
Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis
Zaritsky J, Rastogi A, Fischmann G, Yan J, Kleinman K, Chow G, Gales B, Salusky IB, Wesseling-Perry K, Nephrol Dial Transplant, 1/1/2014
A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM, PA21 Study Group, Kidney Int, 1/1/2014
Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A, Antimicrob Agents Chemother, 1/1/2013
Impact of frequent hemodialysis on anemia management: results from the Frequent Hemodialysis Network (FHN) Trials
Ornt DB, Larive B, Rastogi A, Rashid M, Daugirdas JT, Hernandez A, Kurella Tamura M, Suri RS, Levin NW, Kliger AS, Frequent Hemodialysis Network Trial Group, Nephrol Dial Transplant, 1/1/2013
Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence
Covic A, Rastogi A, BMC Nephrol, 1/1/2013
Effects of 6-times-weekly versus 3-times-weekly hemodialysis on depressive symptoms and self-reported mental health: Frequent Hemodialysis Network (FHN) Trials
Unruh ML, Larive B, Chertow GM, Eggers PW, Garg AX, Gassman J, Tarallo M, Finkelstein FO, Kimmel PL, FHN Trials Group, Am. J. Kidney Dis., 1/1/2013
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI,..., Arthritis Care Res, 1/1/2012
Effects of six versus three times per week hemodialysis on physical performance, health, and functioning: Frequent Hemodialysis Network (FHN) randomized trials
Hall YN, Larive B, Painter P, Kaysen GA, Lindsay RM, Nissenson AR, Unruh ML, Rocco MV, Chertow GM, Frequent Hemodialysis Network Trial Group, Clin J Am Soc Nephrol, 1/1/2012
Join now to see all

Books/Book Chapters

Handbook of kidney transplantation
Chapter: Living Donor Kidney Transplantation
Gabriel M. Danovitch, Rastogi ALippincott, Williams and WilkinsEdition 6th,2017
Peritoneal Dialysis: Types, Procedures and Risks Factor Renal and Urologic Disorders
Chapter: Peritoneal Dialysis and Hyperglycemia
Yadlapati A, Wu K, Njue E, Schomberg J, Rastogi AEditors: Anil K. Agarwal, Loay Salman and Arif Asif.Nova Science Publishers, Inc.2013
Lange Current Essentials: Nephrology and Hypertension
Chapter: Tubulointerstitial Diseases
Rastogi A, Nissenson A. Lerma, BernsMacGraw Hill Professional2011
Lange Current Essentials: Nephrology and Hypertension
Chapter: Urinary Tract Infections
Rastogi A, Nissenson A. Lerma, BernsMacGraw Hill Professional2011
Lange Current Essentials: Nephrology and Hypertension
Chapter: Cystic Diseases of the Kidneys
Rastogi A, Nissenson A. Lerma, BernsMacGraw Hill Professional2011
Lange Current Essentials: Nephrology and Hypertension
Chapter: Nephrolithiasis
Rastogi A, Nissenson A. Lerma, BernsMacGraw Hill Professional2011
Lange Current Essentials: Nephrology and Hypertension
Chapter: Hypertension
Rastogi A, Nissenson A. Lerma, BernsMacGraw Hill Professional2011
Lange Current Essentials: Nephrology and Hypertension
Chapter: Other Inherited Diseases of the Kidneys
Rastogi A, Nissenson A. Lerma, BernsMacGraw Hill Professional2011
Lange Current Essentials: Nephrology and Hypertension
Chapter: Complication of Dialysis
Rastogi A, Nissenson A. Lerma, BernsMacGraw Hill Professional2011
Lange Current Essentials: Nephrology and Hypertension
Chapter: Transplantation
Rastogi A, Nissenson A. Lerma, BernsMacGraw Hill Professional2011
Dialysis: History, Development and Promise
Chapter: Trail-blazing Approaches to Dialysis
Hess CLV, McGuigan H, Rastogi A, Kamgar MEditors: Todd S. Ing, Mohamed A. Rahman, Carl M. Kjellstrand.World Scientific Publishing Company, Singapore2010
Dialysis: History, Development and Promise
Chapter: Looking into the future (with an eye towards the past): Nanotechnology
Nobakht N, Rastogi A, Hernandez A, Nissenson AEditors: Todd S. Ing, Mohamed A. Rahman, Carl M. Kjellstrand.World Scientific Publishing Company, Singapore2010
Dialysis: History, Development and Promise
Chapter: Trail-blazing Approaches to Dialysis, Charles Leonard von Hess and Hugh McGuigan
Kamgar M, Nissenson A, Rastogi AEditors: Todd S. Ing, Mohamed A. Rahman, Carl M. Kjellstrand.World Scientific Publishing Company, Singapore2010
Critical Care Nephrology
Chapter: Renal Replacement Therapy
Rastogi AEdition 2nd,2008
Anemia in Peritoneal Dialysis
Rastogi, A., Nissenson, A.2008
Living Well With Kidney Disease
Chapter: Anemia
Rastogi ANational Kidney FoundationEdition 2nd,2006
Join now to see all

Abstracts/Posters

A novel presentation of Fabry Disease
Farid Arman, Peter D. Lymberopoulos, Niloofar Nobakht, Mohammad Kamgar, Ramy M. Hanna, Carl E. Schulze, Reza Khorsan, Jean Hou, Behnoud Beroukhim, Anjay Rastogi, ASN Kidney Week, Chicago, IL, 1/1/2018
Light chain amyloidosis in a kidney donor
Hania Shakeri, Niloofar Nobakht, Shaker Qaqish, Anthony Sisk, Farid Arman, Ehsan Nobakht, Mohammad Kamgar, Anjay Rastogi, ASN Kidney Week, Chicago, IL, 1/1/2018
case of autosomal recessive Alport's syndrome
Farid Arman, Misak Harutyunyan, Gurpreet Singh, Kevin C. Donohue, Maha Al baghdadi, Rohit Singhal, Niloofar Nobakht, Anjay Rastogi, ASN Kidney Week, Chicago, IL, 1/1/2018
Case of Cardiac Involvement in Fabry�s Disease
Rastogi A, Nobakht N, Kamgar M, Saidian J, Al-Baghdadi M, Arman F, World Congress of Nephrology, Mexico City, Mexico, 1/1/2017
A Review of Bone Disease in Fabry Patients
Rastogi A, Arman F, Mohammed Al-Hassan K, Warnock D, Asaturyan A, Salusky I, World Congress of Nephrology, Mexico City, Mexico, 1/1/2017
Treatment Management and Outcomes in Clostridium difficile Infection (CDI) Patients: Assessing the Impact of Renal Disease
Arman F, Hanna M, Govardhan S, Asaturyan A, Mohammed Ameen K, Al-Baghdadi M, Singhal R, Nobakht N, Kamgar M and Rastogi A, UCLA DOM Research Day, 1/1/2017
CARDINAL Study: A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome
Al-Baghdadi M, Harutyunyan M, Matul J, Lopez C, Nobakht N, Kamgar M, Rastogi A, UCLA DOM Research Day, 1/1/2017
A Phase III study of a novel HIF-PHI in Anemia of Chronic Kidney Disease
Govardhan S, Asaturyan A, Jun DY, Bonilla-Cartanega J, Martinez V. Nobakht N, Kamgar M, Rastogi A, UCLA DOM Research Day, 1/1/2017
A Phase 2b Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects with Autosomal Dominant Polycystic Kidney Disease
Singhal R, Sinclair J, Prentice K, Ornelas L, Liu JY, Nobakht N, Kamgar M, Rastogi A, UCLA DOM Research Day, 1/1/2017
A phase III study of Safety and Efficacy of Finerenone in treatment of Diabetic Kidney Disease
Mohammed Ameen K, Schaffer K, Lymberopoulos P, Arman F, Nobakht N, Kamgar M, Rastogi A, UCLA DOM Research Day, 1/1/2017
Characteristics of Responders and Non-Responders to Phosphate Binder Therapy: A Post Hoc Analysis of a Phase 3 Study
Jurgen Floege, Stuart M. Sprague, Anjay Rastogi, Markus Ketteler, Adrian Covic, Sebastian Walpen, Viatcheslav Rakov, Sylvain Larroque, Pablo E. Pergola, ASN Kidney Week, Chicago, IL, 1/1/2016
Effect of Non-Calcium Phosphate Binders on CKD-MBD Indices in Dialysis Patients: A Post Hoc Analysis of a Phase 3 Study
Markus Ketteler, Stuart M. Sprague, Adrian Covic, Anjay Rastogi, Bruce S, Spinowitz, Sylvain Larroque, Viatcheslav Rakov, Sebastian Walpen, Jurgen Floege, ASN Kidney Week, Chicago, IL, 1/1/2016
Implications of Transporter Studies on Development of Tesevatinib for Polycystic Kidney Disease: Multidrug and Toxin Extrusion (MATE)1/2-K Inhibition
James R. Tonra, Caleb Isringhausen, Kenta Hashizume, Jeegar Patel, John Ryan, Olivier Schueller, David Eiznhamer, Mark Berger, Anjay Rastogi, ASN Kidney Week, Chicago, IL, 1/1/2016
The Interplay between Clostridium Difficile infection (CDI) and Renal Disease: Epidemiology, Treatment Management and Outcomes
Rastogi A, Kullar R, Alipourfetrati S, Arman F, Hanna H, Faiek S, Puzniak L, ASN Kidney Week, Chicago, IL, 1/1/2016
Tyrosine Kinase Inhibitor Tesevatinib for Patients with Autosomal Dominant Polycystic Kidney Disease
Rastogi A, ASN, 1/1/2015
CKD-MBD Indices After 52 Weeks of Sucroferri
Rastogi A, ASN, 1/1/2015
Post Hoc Analysis of Antianemic Agent Use Over 1 year in a Phase 3 Study of Sucroferric Oxyhydroxide
Sprague S, Covic A, Floege J, Ketteler M, Spinowitz B, Rakov V, Botha J, Rastogi A, National Kidney Foundation Meeting, 1/1/2015
CD-MBD Markers in a Phase 3 Study of Sucroferric Oxyhydroxide in Dialysis Patient with Hyperphosphatemia
Ketteler M, Sprague S, Covic A, Rastogi A, Rakov V, Chong E, Floege J, WCN, 1/1/2015
Efficacy, Safety and Pill Burden of Sucroferric Oxyhydroxide, an Iron-based Phosphate Binder, Over 52 Weeks in African American Dialysis Patients
Rastogi A, ASN, 1/1/2015
CKD-MBD Indices After 52 Weeks of Sucroferric Oxyhydroxide, an Iron-Based Phosphate Binder, in African American Dialysis Patients
Rastogi A, ASN, 1/1/2015
Concomitant IV Iron Use Drives Changes in Iron Indices in African America Dialysis Patients Over 52 Weeks of Sucroferric Oxyhydroxide Treatment
Rastogi A, ASN, 1/1/2015
ucroferric Oxyhydroxide Does Not Interact with Oral Vitamin D Receptor Agonist: A Post Hoc Analysis of Phase 3 Data
Coyne D, Sprague S, Chong E, Botha J, Rastogi A, Annual Dialysis Conference, 1/1/2015
Analysis of FGF-23 and Other CKD-MBD Markers ina Phase 3 Study of Sucroferric Oxyhydroxide in CKD Patients on Dialysis
Ketteler M, Sprague S, Covic A, Rastogi A, Rakov V, Chong E, Floege J, WCN, 1/1/2015
Sucroferric Oxyhydroxide Does Not Interact with Oral Vitamin D Receptor Agonist: A Post Hoc Analysis of Phase 3 Data
Coyne D, Sprague S, Chong E, Botha J, Rastogi A, ADC, 1/1/2015
Efficacy and Safety of iron-based Phosphate Binder Sucroferric Oxyhydroxide in CKD Patient on Peritoneal Dialysis or Hemodialysis
Wooldrige T, Sprague S, Rakov V, Botha J, Rastogi A, ADC, 1/1/2015
Join now to see all

Lectures

Hypertension in Elderly
Los Angeles, CA - 1/1/2018
An overview of ADPKD
Los Angeles, CA - 1/1/2018
Updates on Nephrology and ADPKD
Los Angeles, CA - 1/1/2018
EGFR antagonists in ADPKD
Kansas City, KS - 1/1/2018
Velphoro Publication Steering Committee
Zurich, Switzerland - 1/1/2018
Ambulatory Blood Pressure sub-study
Dallas, TX - 1/1/2018
Introduction to Dialysis
Los Angeles, CA - 1/1/2017
Chronic Kidney Disease
Los Angeles, CA - 1/1/2017
Acute Kidney Injury
Los Angeles, CA - 1/1/2017
Immune Complex Glomerulonephritis
Marina Del Rey, CA - 1/1/2017
Fabry�s Disease: What an Internist Should Know
University of California, Los Angeles, CA - 1/1/2017
Fabry�s Disease: The Heart Connection
University of California, Los Angeles, CA - 1/1/2017
Kidney Disease and Hypertension: What You Should Know
Leo Baeck Temple, Los Angeles, CA - 1/1/2017
Fabry�s Disease
University of California, Los Angeles, CA - 1/1/2017
Role of Nephrology in Fabry Disease
Boston, MA - 1/1/2017
Safety of Tesevatinib in ADPKD
Big Sky, MN - 1/1/2017
Renal Updates on Fabry Disease
Ohio State University, Columbus, OH - 1/1/2017
Peritoneal Dialysis Peritonitis
Long Beach, CA - 1/1/2017
Fabry�s Disease: An Update
University of California, San Francisco, CA - 1/1/2016
Home Dialysis
Los Angeles, CA - 1/1/2016
ADPKD
Los Angeles, CA - 1/1/2016
Diet and Nutrition
UCLA Medical Center, Santa Monica Auditorium, Santa Monica, CA - 1/1/2016
General Review of Kidney/ Diet and Nutrition/ Dialysis Modality Education
UCLA Medical Center, Santa Monica Auditorium, Santa Monica, CA - 1/1/2016
Polycystic Kidney Disease
UCLA Tamkin Auditorium B-130, Los Angeles, CA - 1/1/2016
Hypertension Interactive Talk
UCLA Young Research Library, Los Angeles, CA - 1/1/2016
Join now to see all

Other

Renal Sympathetic Denervation for Resistant Hypertension: Rationale and Results
Sharma T, Talwar R, Goshtaseb K, and Rastogi A
1/1/2013
Could You Have Prehypertension?
Rastogi A, UCLA Division of Geriatrics Healthy Years newsletter
1/1/2008
Take Steps Now to Preserve Your Kidney Function
Rastogi A, UCLA Division of Geriatrics Healthy Years newsletter
1/6/2007
Protect your Kidneys from Drug Toxicity
Rastogi A, UCLA Division of Geriatrics Healthy Years newsletter
1/4/2007
Join now to see all

Press Mentions

What to Know About Chronic Kidney Disease in the Wake of Suni Lee’s DiagnosisJuly 29th, 2024
UCLA Jonsson Comprehensive Cancer Center Researchers at ASH 2021 Annual Meeting and ExpositionDecember 14th, 2021
‘Long COVID’ Raises Kidney Damage RiskSeptember 14th, 2021
Join now to see all